Further elucidation of the complex pattern of influence of TAAR1 upon monoaminergic and other pathways controlling mood, motor function and cognition may lead to the elaboration of urgently-need, novel strategies for improving the treatment of depression, schizophrenia, Parkinson’s disease, and other neuropsychiatric disorders (Millan et al., 2015; Khan and Nawaz, 2016; Berry et al., 2017; Cichero and Tonelli, 2017). Here, TAAR1 is linked to depressive disorder.